Lambert syndrome

Common Name(s)

Lambert syndrome

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Lambert syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Lambert syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Lambert syndrome" returned 62 free, full-text research articles on human participants. First 3 results:

Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging in the investigation of Lambert-Eaton myasthenic syndrome.
 

Author(s): Vera L Braatz, Cláudia S K Kay, Paulo J Lorenzoni, Vinicius B Ludwig, Milton M Machota Junior, Sergio O Ioshii, Rosana H Scola, Lineu C Werneck

Journal: Arq Neuropsiquiatr. 2013 Sep;71(9A):643-4.

 

Last Updated: 21 Oct 2013

Go To URL
Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome.
 

Author(s): Tyler B Tarr, Waqas Malick, Mary Liang, Guillermo Valdomir, Michael Frasso, David Lacomis, Stephen W Reddel, Adolfo Garcia-Ocano, Peter Wipf, Stephen D Meriney

Journal: J. Neurosci.. 2013 Jun;33(25):10559-67.

 

We developed a novel calcium (Ca(2+)) channel agonist that is selective for N- and P/Q-type Ca(2+) channels, which are the Ca(2+) channels that regulate transmitter release at most synapses. We have shown that this new molecule (GV-58) slows the deactivation of channels, resulting ...

Last Updated: 20 Jun 2013

Go To URL
Lambert-Eaton myasthenic syndrome and solitary cerebellar metastasis in a patient with occult small-cell lung cancer: a rare experience.
 

Author(s): Sayantan Ray, Nikhil Sonthalia, Supratip Kundu, Subhasis Maitra, Manjari Saha, Arunansu Talukdar

Journal:

 

The authors describe a case of 60-year-old male patient presented with a 6 month history of progressive weakness of all the four limbs, ataxia, droopy eyelids and bulbar features. Further laboratory and electrodiagnostic studies confirmed the diagnosis of Lambert-Eaton myasthenic ...

Last Updated: 18 May 2012

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Lambert syndrome" returned 3 free, full-text review articles on human participants. First 3 results:

Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
 

Author(s): Maarten J Titulaer, Bethan Lang, Jan Jgm Verschuuren

Journal: Lancet Neurol. 2011 Dec;10(12):1098-107.

 

Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular autoimmune disease that has served as a model for autoimmunity and tumour immunology. In LEMS, the characteristic muscle weakness is thought to be caused by pathogenic autoantibodies directed against voltage-gated calcium ...

Last Updated: 18 Nov 2011

Go To URL
Lambert-Eaton myasthenic syndrome.
 

Author(s): U Seneviratne, R de Silva

Journal: Postgrad Med J. 1999 Sep;75(887):516-20.

 

The Lambert-Eaton myasthenic syndrome is a neuromuscular disorder characterised by defective neurotransmitter release at autonomic neurones and presynaptic terminals of the neuromuscular junction. It is caused by an IgG autoantibody formed against especially the P/Q type of voltage-gated ...

Last Updated: 18 Jan 2000

Go To URL
An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
 

Author(s): M Takamori

Journal: Intern. Med.. 1999 Feb;38(2):86-96.

 

The Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease that is often associated with lung cancer which shares a common antigenic protein with the motor nerve terminal. The myasthenic weakness is caused by an antibody-induced reduction in the release of acetylcholine ...

Last Updated: 18 Jun 1999

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Treatment of Lambert-Eaton Syndrome With 3,4 DAP
 

Status: Available

Condition Summary: Lambert Eaton Myasthenic Syndrome

 

Last Updated: 7 Nov 2012

Go to URL
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
 

Status: Available

Condition Summary: Lambert-Eaton Myasthenic Syndrome

 

Last Updated: 22 Feb 2011

Go to URL
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
 

Status: Recruiting

Condition Summary: Lambert-Eaton Myasthenic Syndrome; Congenital Myasthenic Syndrome

 

Last Updated: 22 May 2013

Go to URL